This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Announces Presentations At 2nd Baltic Stem Cell Meeting And Session To Feature VSEL(TM) Technology

NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that Company management will make two presentations at the 2 nd Baltic Stem Cell Meeting, running from Friday, May 31 to Sunday, June 2, 2013, and that the conference will feature a session with multiple researchers from around the world discussing advances using very small embryonic-like stem cells (VSELs™ Technology).

The conference focuses on innovative applications of stem cells in multiple areas, the clinical application of umbilical cord blood in regenerative medicine, news and updates on VSEL™ Technology, stem cell mobilization and homing, novel directions in hematopoietic transplants, stem cells and cancer, stem cells and aging, and more. Dr. Robin L. Smith, Chairman and CEO of NeoStem, will chair a panel and give a talk titled "From the bench to the clinic: Considerations in cell therapy development." Dr. Denis O. Rodgerson, Director of Stem Cell Science of NeoStem, will speak on "Generation of skeletal structures by human very small embryonic-like (VSEL) stem cells."

The conference will also feature some of the researchers from the United States, Europe and Asia who have expanded on the initial studies of VSEL™ Technology carried out by Dr. Mariusz Ratajczak, including:
  • Dr. Diane Krause of Yale University will speak on her recent research on the differentiation of VSELs from murine bone marrow into lung epithelial cells. This research will be published in Stem Cells, May 2013 issue.
  • Dr. Magdalena Kucia of the University of Louisville will speak on "Aging – when VSELs meet IGF-1."
  • Dr. Yu-Zhu Tan will speak on "Repairing the infarcted myocardium by transplantation of very small embryonic-like stem cells."
  • Dr. Marcin Moniuszko will speak on "Effects of vascular dysfunction on circulating endothelial progenitor cells and VSEL stem cells in type 1 diabetes."
  • Dr. Deepa Bhartiya of the National Institute for Research in Reproductive Health, Mumbai, India will present on "VSELs in adult mammalian gonads."
  • Dr. Dong-Myung Shin of the University of Louisville will present on "Molecular signature of murine and human Oct4+ very small embryonic-like stem cells (VSELs)."

"The research being presented by these scientists both enhances our understanding of the potential of VSELs as the ultimate cell for regenerative therapy and provides further validation of the capabilities of these cells," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We are happy to see research into VSEL™ Technology by a growing number of scientists who are not affiliated with NeoStem and we welcome the interest of the scientific community in these extraordinary cells."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.03 -1.20%
FB $117.60 0.14%
GOOG $696.51 0.60%
YHOO $35.96 -0.14%
TSLA $221.80 -4.50%


Chart of I:DJI
DOW 17,646.54 -104.37 -0.59%
S&P 500 2,049.42 -13.95 -0.68%
NASDAQ 4,722.6130 -40.6110 -0.85%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs